CD274 and posterior cortical atrophy: In particular, no overall survival (OS) benefit has been observed in patients treated with ipilimumab [7–9], whereas monotherapies directed against PD1 or PD-L1 have only demonstrated limited response in PCa patients, probably due to an immunologically cold PCa microenvironment [10].